stockrow
Saturday 7 November 2026
Export SVRA’s income statement to Excel — free account
Savara Inc.
SVRA Healthcare Biotechnology
- EPS
- −14.3%
- Free cash flow
- −14.1%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
4.83
0.45
+10.27%
Follow SVRA
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
9.83 | 13.05 | 11.56 | 7.42 | |
Current Ratio |
10.13 | 13.47 | 11.85 | 7.65 | |
Net Debt/EBITDA |
3.47 | 4.39 | 6.10 | 3.10 | |
Debt/Assets |
15.67% | 13.57% | 11.80% | 21.13% | |
Debt/Equity |
0.21 | 0.17 | 0.15 | 0.32 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.89 | 0.78 | 0.76 | |
Capex/Depreciation |
0.79 | 0.16 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.12) | (0.13) | (0.11) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.13) | (0.11) | (0.10) | |
Cash per Share |
0.68 | 0.80 | 1.06 | 0.57 | |
Shareholders Equity per Share |
0.57 | 0.70 | 0.91 | 0.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.57 | 0.70 | 0.91 | 0.44 | |
Free Cash Flow |
(29.97) | (33.10) | (25.06) | (22.53) | |
Working Capital |
160.72 | 193.73 | 221.22 | 111.44 | |
Capital Expenditures |
(0.22) | (0.05) | 0.00 | 0.00 | |
Net Current Asset Value |
129.84 | 163.66 | 191.31 | 81.66 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.87 | 5.03 | 5.15 | 4.37 | |
Average Assets |
177.95 | 205.48 | 233.16 | 189.87 | |
Average Common Equity |
132.07 | 161.94 | 187.29 | 146.87 |
Columns are period end dates · fundamentals updated 25 Oct 2026